The appointment of Dr Roberts significantly strengthens the Lentitek team both commercially and scientifically. Founded in 2019 by Dr Adam Inche, Lentitek had developed a technology which addresses key issues within the manufacturing of advanced cell and gene therapies. These advanced therapies provide curative treatments for previously intractable cancers and other genetic conditions but are difficult and expensive to manufacture and deliver. Since incorporation Lentitek has moved rapidly to develop and commercialise its unique technology attracting significant interest from major players in the field.
“Lentitek’s unique technology and application to advanced cell and gene therapy markets has close parallels to those which Dr Roberts commercialised so successfully at Synpromics. By leveraging his experience our team hopes to rapidly build on our strong initial successes in the market place.”
On his appointment as Director at Lentitek, Dr Roberts commented: “I have been keenly interested in Lentitek and was delighted to be asked to join the team. Their technology provides an elegant solution to some of the most pressing concerns in lentivirus manufacturing.” Roberts currently serves as CEO for Chromatin Bioscience Ltd, a leading provider of synthetic promoter design services for the cell and gene therapy sector with a prestigious list clients.
Lentitek Co-Founder Leif Anderson said: “Winning such a competitive grant is a tremendous endorsement of the technology and team Lentitek has built since incorporating. With Michael to guide us I believe the business is poised to make a real difference to the market and to patient outcomes.”
More information can be found at the UKRI page.
ENDS